New insider activity at Jazz Pharmaceuticals ( (JAZZ) ) has taken place on December 9, 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Patricia Carr, the Senior Vice President and Chief Accounting Officer of Jazz Pharmaceuticals, has recently sold 4,660 shares of the company’s stock. This transaction was valued at an impressive $797,777.
Recent Updates on JAZZ stock
Recent developments in Jazz Pharmaceuticals’ stock have seen several price target adjustments from analysts, driven primarily by positive outcomes from the Phase 3 HERIZON-GEA-01 study. UBS downgraded the stock to Neutral, citing a balanced risk/reward profile after a significant stock move and the recent oncology momentum being reflected in the valuation. In contrast, Truist, Baird, BofA, and Wells Fargo raised their price targets, highlighting the promising potential of Jazz’s drug Ziihera, which is seen as a ‘pipeline-in-a-drug’ with significant sales potential in HER2+ cancers. The favorable study results suggest Ziihera could become a new standard of care in gastric cancer, with substantial market opportunities both in the U.S. and globally.
Spark’s Take on JAZZ Stock
According to Spark, TipRanks’ AI Analyst, JAZZ is a Neutral.
Jazz Pharmaceuticals’ overall score is driven by strong earnings call results and positive corporate events, indicating strategic growth potential. However, financial performance challenges and valuation concerns weigh on the score.
To see Spark’s full report on JAZZ stock, click here.
More about Jazz Pharmaceuticals
YTD Price Performance: 36.51%
Average Trading Volume: 985,120
Technical Sentiment Signal: Buy
Current Market Cap: $10.31B